度伐利尤单抗用于III期EGFR突变NSCLC根治性放化疗后
多机构回顾性分析37例不可切除III期EGFR突变NSCLC完成同步放化疗的患者,13例接受度伐利尤单抗巩固治疗,24例未接受。度伐利尤单抗组中位PFS为10.3个月,单纯放化疗组为6.9个月(log-rank p=0.993),差异无统计学意义;放化疗联合EGFR-TKI组中位PFS为26.1个月,显著优于其他两组(log-rank p=0.023)。度伐利尤单抗组免疫相关不良事件发生率高,且后续使用奥希替尼可能出现严重肺炎。
要点
- EGFR突变III期NSCLC放化疗后度伐利尤单抗巩固未显著改善PFS。
- 放化疗联合EGFR-TKI中位PFS达26.1个月,显著优于其他策略。
- 度伐利尤单抗后序贯奥希替尼需警惕免疫相关不良事件。
核心结论
- EGFR突变NSCLC患者未能从度伐利尤单抗巩固治疗中获益,且免疫相关不良事件发生频率高。
- 度伐利尤单抗后启动奥希替尼的患者可能易发生免疫相关不良事件。
研究设计与样本
- 多机构回顾性分析,纳入37例不可切除III期EGFR突变NSCLC完成同步放化疗的患者。
主要发现
- 13例在放化疗完成后中位20天启动度伐利尤单抗,其中2例完成12个月治疗,5例因进展停药,5例因免疫相关不良事件停药。
- 24例未接受度伐利尤单抗,其中16例单纯放化疗,8例放化疗联合诱导或巩固EGFR-TKI。
- 度伐利尤单抗组中位PFS为10.3个月,单纯放化疗组为6.9个月(log-rank p=0.993)。
- 放化疗联合EGFR-TKI组中位PFS为26.1个月,显著长于度伐利尤单抗组或单纯放化疗组(log-rank p=0.023)。
- 6例度伐利尤单抗治疗后复发启动EGFR-TKI,其中1例使用奥希替尼发生4级肺炎。
临床怎么用
- EGFR突变III期NSCLC根治性放化疗后应谨慎使用度伐利尤单抗巩固治疗。
- 放化疗联合诱导或巩固EGFR-TKI值得进一步研究作为根治性治疗策略。
- 度伐利尤单抗后序贯奥希替尼需密切监测免疫相关不良事件。
局限性
- 回顾性分析,样本量小(37例),可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In 2018, durvalumab was approved by the U.S. Food and Drug Administration as consolidation immunotherapy for patients with stage III NSCLC after definitive chemoradiotherapy (CRT). However, whether durvalumab benefits patients with EGFR-mutated NSCLC remains unknown. METHODS: We conducted a multi-institutional retrospective analysis of patients with unresectable stage III EGFR-mutated NSCLC who completed concurrent CRT. Kaplan-Meier analyses evaluated progression-free survival (PFS) between patients who completed CRT with or without durvalumab. RESULTS: Among 37 patients, 13 initiated durvalumab a median of 20 days after CRT completion. Two patients completed 12 months of treatment, with five patients discontinuing durvalumab owing to progression and five owing to immune-related adverse events (irAEs). Of 24 patients who completed CRT without durvalumab, 16 completed CRT alone and eight completed CRT with induction or consolidation EGFR tyrosine kinase inhibitors (TKIs). Median PFS was 10.3 months in patients who received CRT and durvalumab versus 6.9 months with CRT alone (log-rank p = 0.993). CRT and EGFR TKI was associated with a significantly longer median PFS (26.1 mo) compared with CRT and durvalumab or CRT alone (log-rank p = 0.023). Six patients treated with durvalumab initiated EGFR TKIs after recurrence, with one developing grade 4 pneumonitis on osimertinib. CONCLUSIONS: In this study, patients with EGFR-mutated NSCLC did not benefit with consolidation durvalumab and experienced a high frequency of irAEs. Patients who initiate osimertinib after durvalumab may be susceptible to incident irAEs. Consolidation durvalumab should be approached with caution in this setting and concurrent CRT with induction or consolidation EGFR TKIs further investigated as definitive treatment.
引用
- Aredo JV, Mambetsariev I, Hellyer JA, et al. Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. J Thorac Oncol. 2021. PMID: 33588109. doi:10.1016/j.jtho.2021.01.1628
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。